Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ultragenyx Pharmaceutical Inc.

www.ultragenyx.com

Latest From Ultragenyx Pharmaceutical Inc.

Keeping Track: A Novel Approval For Fluorodopa F 18, A Tentative Approval For Vumerity, And A Missed Goal Date For Zilretta

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Approvals

Approval Positions Roxadustat As Japan HIF-PHI Pioneer

The latest batch of product approvals in Japan positions Astellas’s roxadustat as the pioneer in the country’s potentially large HIF-PH inhibitor market in anemia, while Takeda and Meiji Seika see other important approvals and the first biosimilar teriparatide receives a nod.

Japan Approvals

Keeping Track: CDER Ties Monthly Novel Approval Record With Nourianz Green Light

The latest drug development news and highlights from our US FDA Performance Tracker. 

Approvals Drug Review

Interview: Mereo All Set For Key Setrusumab Data

Although far from a one-product company, data in Q4 will be key to whether the brittle bone drug could become a blockbuster for the UK NASDAQ-listed biotech.

Strategy Orthopedics
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ultragenyx Pharmaceutical LLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ultragenyx Pharmaceutical Inc.
  • Senior Management
  • Emil Kakkis, MD, PhD, Pres. & CEO
    Shalini Sharp, EVP, CFO
    Thomas Kassberg, EVP, CBO
    Camille L Bedrosian, MD, EVP, CMO
    Vlad Hogenhuis, MD, COO
    Erik Harris, EVP, Chief Commercial Officer
  • Contact Info
  • Ultragenyx Pharmaceutical Inc.
    Phone: (415) 483-8800
    60 Leveroni Ct.
    Novato, CA 94949
    USA
UsernamePublicRestriction

Register